Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
gold bullion fundamentals:
DJ FOCUS: Gold Miners See More Upside For Yellow Metal
Fri Aug 12 04:48:40 2005 EST
By James Attwood
Of DOW JONES NEWSWIRES
SYDNEY (Dow Jones)--Largely left behind in the ongoing China-led commodities
boom, gold miners are increasingly turning confident that the precious metal's
improving fundamental outlook and the continuing pressure on the U.S. dollar
signal a change in their fortunes.
Producers of nickel, zinc, iron ore and coal boasted record profit and bold
expansion plans at this week's Diggers & Dealers mining forum in Kalgoorlie,
Western Australia, as China's insatiable appetite for raw materials hogged most
of the limelight.
In contrast, delegates from global gold miners Newmont Mining Corp. (NEM),
AngloGold Ashanti Ltd. (AU), Placer Dome Inc. (PDG) and Barrick Gold Corp.
(ABX) outlined cost-cutting initiatives and ways to diversify risk.
While most industrial materials have hit, or look set to hit, the top of the
current cycle, producers were talking of the likelihood of a sustained rally in
gold prices.
Steadily growing physical demand, especially in jewelry, and supply-side
constraints make for a positive fundamental outlook, said Johannesburg-based
AngloGold Ashanti, the world's second-largest producer of gold.
In addition, concerns over the U.S. deficit and Euro-zone cohesion mean
speculators are holding significant net long positions in gold, said Roberto
Carvalho Silva, chief operating officer of AngloGold Ashanti's international
division.
"Investors are feeling certain economic uncertainties and that is a driver to
look for a real store of value," he told Dow Jones Newswires on the sidelines
of the forum.
"So, people are putting more money into physical commodities and there is no
better commodity than gold," Carvalho said.
Upside Bias Seen In Prices
Gregory Wilkins, chief executive of Barrick's Australian operation, agreed
that the bias for U.S. dollar-denominated gold is to the upside against a
backdrop of improving fundamentals.
Without offering price forecasts, Wilkins pointed to gold's recent decoupling
from its traditional close correlation with the Euro, after France and Belgium
rejected the European Union's constitution.
"People are going to be concerned about diversifying into the Euro," he said.
"So where else do you go?"
However, the direction in gold prices has to be seen in the long-term
context, Wilkins said.
"You can't judge gold price on day-by-day trading anomalies," he said,
referring to the fall in prices Monday just after South African miners began a
general strike, and the rally to a five-month high overnight as the strike came
to an end.
"We look at a longer-term horizon (and see) growth in jewelry off-take and
central banks taking themselves out of the equation," he said.
Like other delegates at the conference, Wilkins painted a bearish outlook for
the U.S. dollar, which in turn is usually interpreted as bullish for gold given
their traditional inverted correlation.
The bleak dollar picture is based on unsustainable trade and current account
deficits and inflationary concerns in the U.S., especially in the housing
market.
"It's going to really damage the U.S. economy and the Fed will not really be
in a position to raise rates to curtail some of the problems they are going to
have because they'd just bankrupt the consumer," he said.
Supply Constraints A Double-Edged Sword
Another fundamental factor supporting gold is the soaring cost of oil, steel
and other inputs, combined with tight labor and equipment markets as gold
miners and explorers compete with miners of other booming industrial
commodities.
The constraints are a doubled-edged sword for producers. Margins are being
squeezed as operating costs rise, while escalating development costs limit the
feasibility of new projects and expansions.
For the gold majors at Diggers & Dealers, cost saving was a constant theme,
with most looking to grow their reserves via expansions at existing operations
rather than new greenfield projects.
"Yes, we're under some cost pressures. We're doing business improvements to
prevent the impact of those (and) we're looking at US$80 million in savings,"
said Joc O'Rourke, Placer Dome Asia Pacific's general manager, echoing the
comments of several others.
The constraints are of particular concern in the companies' established
mining destinations of South Africa, Australia and North America, where local
currency strength has added to the pressure.
Besides efficiency programs, the answer, according to delegates, was in the
world's new mining frontiers of South America, Africa, Russia, China and
Mongolia, for example.
Meanwhile, the companies said they continue to chip away at their hedge books
to give shareholders more exposure to gold's upside potential.
-By James Attwood, Dow Jones Newswires; 612-8235-2965;
james.attwood@dowjones.com
-Edited by Denny Kurien
(END) Dow Jones Newswires
08-12-05 0449ET
Copyright (c) 2005 Dow Jones & Company, Inc.
04:49 081205
--------------------------------------------------------------------------------
Dec gold brk/out continues: + 7.20 to 449.30...eom
BTN.F trading + .06 to 2.30 euro(usd=2.85) on 40k shs, 2.27/2.33 euro...
b nice to c this translate 2 the U.S. open
Biophan Details Recent Key Business and Technology Achievements in Corporate strategic Overview for First Half of 2005; Mid-Year Review Outlines Milestone Acquisitions, Technology Licensing Agreements and Other Progress
excerpt" Additionally, Biophan and technology partner, New Scale Technologies, announce the newly allowed
fundamental patent on tiny, nano-precise MRI-compatible SQUIGGLE motor. The U.S. Patent and Trademark Office issued the fundamental patent for this revolutionary linear motor made of piezoelectric ceramics and other non-magnetic materials,
which achieves nanometer precision."
ROCHESTER, N.Y., Aug 11, 2005 (BUSINESS WIRE) -- Biophan Technologies, Inc.
(OTCBB:BIPH), a developer of next-generation medical technology, has reported
significant progress in several key corporate areas in a business review of the
first half of 2005. The mid-year review describes key achievements and
milestones, such as the acquisition of an advanced research and development
company, the execution of a licensing agreement with a leading medical device
manufacturer, and the continued expansion of its intellectual property
portfolio.
"Our achievements so far this year have been pivotal in Biophan's strategic
mission to provide significant medical products and advances to capitalize on
several multi-billion-dollar markets around the world," said Michael Weiner,
Biophan CEO. "One of the highlights of the last two calendar quarters was our
acquisition of AMRIS and the concurrent establishment of our Biophan Europe
division, closing of equity and licensing agreements with Boston Scientific, and
the continued expansion of our intellectual property portfolio. These events
have resulted in increased shareholder value and stronger support from the
investment community."
Biophan's mission is to develop technologies that offer our customers
competitive advantage. Our primary technology solutions are intended to enable a
new generation of implanted medical devices and surgical tools that work safely
and effectively with Magnetic Resonance Imaging (MRI) systems. Due to safety and
image compatibility problems, millions of people with pacemakers,
neurostimulators and other devices cannot be exposed to the MRI environment. We
are also developing technology that will enable devices that are safe, such as
stents, to be internally imageable under MRI, where today an invasive catheter
procedure is needed. Furthermore, the company is pursuing concepts for advances
in drug delivery technology.
Biophan also develops devices to address important needs in the biomedical
marketplace, including a line of ultra-precise, MRI-safe motors for
drug-delivery and other applications, and biothermal power sources that convert
body heat into electricity to power medical devices such as pacemakers. The
Company has recently launched a new initiative to develop cardiovascular devices
for diagnostic and therapeutic applications in heart disease. These will be
licensed or sold through partners with existing distribution, and not sold
directly by Biophan.
The Company's milestones for 2005 thus far include the following achievements:
Licensing and Equity Agreements
-- Execution of licensing and equity agreements in June with leading medical
device manufacturer Boston Scientific. Under the agreement, Boston Scientific
will license multiple Biophan patents related to MRI safety and image
compatibility which, along with a concurrent equity agreement, results in $5.75
million in equity investment and upfront licensing payments. Details in the
license agreement, as disclosed in the 10-Q for the first quarter 2005, provide
Boston Scientific with the right to use Biophan's MRI safety and image
compatibility technology and other technologies in a broad range of exclusive
and non-exclusive product areas at royalty rates of 3% to 5%. The exclusive
product area includes vascular implants and the non-exclusive product area
covers a broad array of products including guidewires, catheters, pacemakers,
defibrillators, neurostimulators and others. Boston Scientific has the right to
sub-license the exclusive product areas to third parties, with Biophan and
Boston Scientific to share all proceeds from these parties. The agreement also
provides for milestone payments to Biophan for specific product areas.
Acquisitions
-- In May, Biophan completed the acquisition of AMRIS GmbH, a company in Germany
that develops solutions to create MRI-compatible stents, vena cava filters and
other devices. (To see an example of these technologies click here for stents:
http://www.biophan.com/presentations/MRIImage.ppt and for vena cava filters
click here: http://www.biophan.com/presentations/042605VCF.ppt). The acquisition
dramatically increases Biophan's access to MRI equipment and expert personnel,
as well as expanding its intellectual property portfolio through the addition of
15 patents related to MRI safety and image-compatibility. Following the
acquisition, the Company designated and renamed it Biophan Europe. The group is
leading the Company's research and business initiatives in Europe. "The
acquisition of AMRIS and its establishment as the Company's Biophan Europe
division was one of the year's most important achievements," said Mr. Weiner.
"It strengthened Biophan through the addition of key AMRIS personnel, as well as
by providing the Company with unique access to the European research community,
where some of the most exciting research into MRI is being conducted." Biophan
Europe is a leader in development of technologies that make vascular stents and
other devices imageable under MRI, and in the emerging field of Interventional
MRI which uses the safer imaging modality of MRI to conduct advanced, minimally
invasive surgical procedures.
Listing on a Major Exchange
-- With the completion of the Boston Scientific agreements and the subsequent
payment to Biophan of $5.75 million, Biophan is now preparing to file for
listing on a major exchange. It is anticipated that the listing will be
completed sometime in the second half of 2005.
Intellectual Property Expansion
-- In the first half of calendar 2005, Biophan added 38 patents, licenses or
applications to reach a total of 140. This intellectual property further
reinforced the Company's strategic goal to capitalize on its proprietary
nanotechnology and other cutting-edge solutions to make implantable medical
devices and surgical tools safe and image-compatible with Magnetic Resonance
Imaging (MRI) systems. The Company continued to strengthen an extensive patent
portfolio designed to provide the maximum protection of its marketable
technology solutions. The new technologies and patents cover
nanotechnology-based implantable power sources that convert body heat to
electricity, nanomagnetic device coatings, specialized dielectric materials,
photonic diagnostics and therapies, and other innovations. Additionally, Biophan
and technology partner, New Scale Technologies, announce the newly allowed
fundamental patent on tiny, nano-precise MRI-compatible SQUIGGLE motor. The U.S.
Patent and Trademark Office issued the fundamental patent for this revolutionary
linear motor made of piezoelectric ceramics and other non-magnetic materials,
which achieves nanometer precision.
Industry Recognition, Press and Presentations
-- Biophan CEO Michael Weiner was featured on World Talk Radio's "Science and
Society" program, in an online audio interview aired in June with host Dr. David
Lemberg that focused on Biophan's groundbreaking scientific advances in several
multi-billion-dollar biomedical markets.
-- Biophan and New Scale Technologies announce that the SQUIGGLE motor is named
to EE Times' Top Ten "Most Significant" Products List in June. This novel linear
motor has nanometer precision and is made of non-magnetic materials, making it
safe and compatible for use with MRI for implantable and robotic applications.
-- In April, Biophan CEO Michael Weiner was an expert panelist on the
Nanotechnology Patents Panel at NanoScience Exchange Conference, in Santa Clara,
California, entitled "Patents: Who's Staked the Valuable Turf?" The two-hour
discussion covered the potential impacts and opportunities of nanotechnology on
the multi-billion-dollar healthcare market.
-- Biophan CEO Michael Weiner was an expert commentator at the World
Nano-Economic Congress Ireland in Dublin. Mr. Weiner was interviewed twice on
CNBC Frankfurt by Sylvia Whadwa, and appeared on CBS MarketWatch, CBS News,
Chicago, WGN cable television, and many other forums and television and radio
shows.
-- In February, Biophan was included in BusinessWeek magazine's cover story
about the latest innovations in nanotechnology. The cover story, entitled "The
Business of Nanotech," describes the progression of nanotechnology from the
laboratories to a burgeoning marketplace involving key industries, including
healthcare, automotive, energy, computers and semiconductors, advanced consumer
materials, and many others. In the BusinessWeek article, Biophan is listed as
one of the seven nanotechnology players in the healthcare sector along with
General Electric, Johnson & Johnson, NASA, and others.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make
biomedical devices safe and image compatible with the magnetic resonance imaging
(MRI) environment. The Company develops technologies that enable implanted
medical systems such as pacemakers, interventional surgical devices such as
catheters and guidewires, and devices such as stents to be safely and
effectively imaged under MRI. Biophan is developing these same technologies to
provide new MRI contrast agents. Other applications include drug delivery and
power systems derived from body heat. Four Biophan technologies include advances
in nanotechnology and thin film coatings. Committed to growth through innovation
and developmental leadership, Biophan and its licensors now hold a total of 142
U.S. patents, licenses, or applications. This total includes 38 issued U.S.
patents, 9 recently-allowed applications that will issue as patents in the near
future, and 95 pending applications at various stages of examination at the U.S.
Patent and Trademark Office, plus international applications. The patents cover
areas including nanotechnology (nanomagnetic particle coatings), medical device
designs, radio frequency filters, polymer composites, thermoelectric materials
for batteries generating power from body heat, and photonics. Biophan has joint
development and licensing agreements with Boston Scientific (NYSE:BSX) and
NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical
devices capable of safely and successfully working with MRI, and delivering
other technologies which will improve quality of life. For more information,
please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking
statements within the meaning of applicable securities laws. These statements
reflect what Biophan anticipates, expects, or believes may happen in the future.
Biophan's actual results could differ materially from the outcome or
circumstance expressed or implied by such forward-looking statements as a result
of a variety of factors including, but not limited to: Biophan's ability to
develop its technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development programs; the
ability of Biophan to demonstrate the effectiveness of its technology; the
acceptance by the market of Biophan's technology and products incorporating such
technology, the ability of Biophan to effectively negotiate and enter into
contracts with medical device manufacturers for the licensing of Biophan's
technology; competition; the ability of Biophan to raise capital to fund its
operating and research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in Biophan's
periodic filings with the Securities and Exchange Commission (the "SEC"). As a
result, this press release should be read in conjunction with Biophan's periodic
filings with the SEC which are incorporated herein by reference. The
forward-looking statements contained herein are made only as of the date of this
press release, and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Biophan Technologies, Inc.
CONTACT: Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Jennifer Gould, 212-843-8037
Copyright Business Wire 2005
-0-
KEYWORD: United States
Germany
Europe
North America
New York
INDUSTRY KEYWORD: Technology
Other Technology
Health
Biotechnology
Medical Devices
Research & Science
Other Health
Mack: gold update..dec gold is trading nicely above its 431(basis spot) brk/out lvl..
gold has 4 the most part decoupled from int rate concerns- hence its steady price action ystrdy in spite of the fed rate+..
today's positive price action( + 2.10 to 441.90) is also encouraging in that the euro failed to take out restnc @ 1.2460
the US Treasury budget statmnt scheduled for 2 PM today will likely impact this PM's trading..
Dec gold luks higher with a 470 initial price objctv..
wud continue to stay long with a 432(basis spot) stop..
BIPH: Beacon Equity Resch Rpt...
Biophan Technologies Research Note On Boston Scientific Research Issued By Investrend Research Affiliate Beacon Equity Research Analyst
(excerpt:Boston Scientific is currently trying to gain
market share from Johnson & Johnson (NYSE: JNJ) and Guidant Corp. (NYSE: GDT) in the lucrative stent market. Boston likely has plans to use Biophan's technology to open a new market niche.")
(financialwire.net via COMTEX) -- August 4, 2005 (FinancialWire) (Investrend
Research Syndicate) A new research note on Biophan Technologies (OTCBB: BIPH)
has been issued by Beacon Equity Research Senior Analyst, Shailesh Dhuri
regarding the closing of an equity agreement with Boston Scientific Corp. (NYSE:
BSX).
The full report is available at http://www.beaconequityresearch.com and
http://www.investrendresearch.com
In the report, Mr. Dhuri writes, "Biophan entered into a comprehensive agreement
on June 30th of this year with leading biomedical manufacturer, Boston
Scientific Corporation. The agreement called for an equity investment in Biophan
by Boston Scientific and a payment for technology licenses. The equity
transaction consists of Boston Scientific purchasing Biophan common stock
totaling $5 million, priced at a 10% premium over the average of the closing
price for the 30 calendar-day period prior to the closing (which should be over
$3.00 per share at current prices).
"The technology license includes an upfront payment of $750,000 and annual
maintenance fees, in addition to royalties and milestone payments to Biophan.
The license agreement covers multiple patents related to Magnetic Resonance
Imaging (MRI) safety and image compatibility, and includes both exclusive and
non-exclusive product categories. Boston Scientific is currently trying to gain
market share from Johnson & Johnson (NYSE: JNJ) and Guidant Corp. (NYSE: GDT) in
the lucrative stent market. Boston likely has plans to use Biophan's technology
to open a new market niche."
Beacon Equity Research, LLC is a fee-based, comprehensive investment research
firm, focusing primarily on the underserved small-cap sector. All Beacon
analysts are seasoned industry professionals and adhere to the CFA Institute's
(CFAI) stringent ethics and standards of practice guidelines. Beacon Research
does not have any investment banking relationships with any of the companies
covered. All analysts are compensated prior to performing their investment
research and are not compensated in any way based on the future performance of
the equities they follow.
Both Beacon Equity Research and Investrend subscribe to the "Standards for
Independent Research Providers" at http://www.firstresearchconsortium.com .
Beacon Research has been compensated a total of $18,000 by Biophan Technologies
for a one-year enrolment in its research program.
Complete information is available at the company's InvestorPower page at
http://www.investrend.com/company/list.asp?sPathParam=yes . Investors are
advised to read disclosures carefully before trading in the equities of any
enrolled company.
Anyone interested in receiving alerts regarding Biophan Technologies research
should email contact@investrend.com with "BIPH" in the subject line.
For up-to-the-minute news, features and links click on
http://www.financialwire.net
FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
http://www.investrend.com/contact.asp
The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268
URL: http://www.financialwire.net
(C) 2005 financialwire.net, Inc. All rights reserved.
-0-
*** end of story ***
Biophan Posts Presentation Outlining Progress in Growth of Company's Biophan Europe Division; Online Presentation Describes Technologies and Application Development for Advances in MRI Visualization of Medical Devices
ROCHESTER, N.Y., Aug 02, 2005 (BUSINESS WIRE) -- Biophan Technologies, Inc.
(OTCBB: BIPH - News), a developer of next-generation biomedical technology, has
announced the online availability of an electronic presentation that provides a
detailed overview of the Company's Biophan Europe division, including a review
of their key research and product development initiatives. Biophan Europe, based
in Germany, is developing breakthrough solutions that make lifesaving
implantable medical devices, such as vascular stents, clearly imageable under
Magnetic Resonance Imaging (MRI).
The presentation was part of an address given by Biophan Europe President and
CEO, Dr. Michael Friebe, at Biophan's recent annual shareholders meeting in
Rochester, New York. It also describes the extensive European network of
world-class MRI research centers that help maintain Biophan Europe's
cutting-edge position.
Earlier this year, Biophan acquired AMRIS GmbH, a company based in
Castrop-Raxel, Germany, that was developing advanced solutions in MRI
visualization that complemented Biophan's own technologies. Following the
acquisition, AMRIS was renamed Biophan Europe. The establishment of Biophan
Europe gave Biophan access to a large network of leading MRI partner research
centers, including the University of Aachen. It also brought access to extremely
valuable testing facilities at the AMRIS subsidiary, MR:comp GmbH
(www.mrcomp.com), one of the few independent and most advanced MRI test
laboratories in the world.
"Acquiring AMRIS as our Biophan Europe division has been one of our Company's
most significant moves," said Biophan CEO, Michael Weiner. "We have been
strengthened by the addition of the key AMRIS personnel to our ranks, as well as
by the unique access to the European research community, where some of the most
exciting research into MRI is being conducted. One of the many advanced areas
where Biophan Europe is a leader is the emerging field of interventional MRI,
which uses the safer imaging modality of MRI to conduct a new class of advanced,
minimally invasive surgical procedures."
Mr. Weiner added: "As this online presentation describes, Biophan Europe is
positioned to help us accelerate our development and introduction of new
products into the marketplace."
In addition to Dr. Friebe, Biophan Europe's key scientific collaborators include
Dr. Andreas Melzer, a recognized world authority on MRI visualization
technology, and Gregor Schaefers, CEO of MR:comp.
MRI visualization technologies developed at Biophan Europe include "active" as
well as "passive" solutions that enable MRI visualization of stents, catheters,
filters, and other new applications.
Dr. Friebe's presentation, and others delivered at the meeting can be viewed
online at http://www.biophan.com/presentations.php.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make
biomedical devices safe and image compatible with the magnetic resonance imaging
(MRI) environment. The Company develops technologies that enable implanted
medical systems such as pacemakers, interventional surgical devices such as
catheters and guidewires, and devices such as stents to be safely and
effectively imaged under MRI. Biophan is developing these same technologies to
provide new MRI contrast agents. Other applications include drug delivery and
power systems derived from body heat. Four Biophan technologies include advances
in nanotechnology and thin film coatings. Committed to growth through innovation
and developmental leadership, Biophan and its licensors now hold a total of 142
U.S. patents, licenses, or applications. This total includes 38 issued U.S.
patents, 9 recently-allowed applications that will issue as patents in the near
future, and 95 pending applications at various stages of examination at the U.S.
Patent and Trademark Office, plus international applications. The patents cover
areas including nanotechnology (nanomagnetic particle coatings), medical device
designs, radio frequency filters, polymer composites, thermoelectric materials
for batteries generating power from body heat, and photonics. Biophan has joint
development and licensing agreements with Boston Scientific (NYSE: BSX - News)
and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all
biomedical devices capable of safely and successfully working with MRI, and
delivering other technologies which will improve quality of life. For more
information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking
statements within the meaning of applicable securities laws. These statements
reflect what Biophan anticipates, expects, or believes may happen in the future.
Biophan's actual results could differ materially from the outcome or
circumstance expressed or implied by such forward-looking statements as a result
of a variety of factors including, but not limited to: Biophan's ability to
develop its technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development programs; the
ability of Biophan to demonstrate the effectiveness of its technology; the
acceptance by the market of Biophan's technology and products incorporating such
technology, the ability of Biophan to effectively negotiate and enter into
contracts with medical device manufacturers for the licensing of Biophan's
technology; competition; the ability of Biophan to raise capital to fund its
operating and research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in Biophan's
periodic filings with the Securities and Exchange Commission (the "SEC"). As a
result, this press release should be read in conjunction with Biophan's periodic
filings with the SEC which are incorporated herein by reference. The
forward-looking statements contained herein are made only as of the date of this
press release, and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Biophan Technologies, Inc.
CONTACT: Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Jennifer Gould, 212-843-8037
Copyright Business Wire 2005
-0-
KEYWORD: United States
Germany
Europe
North America
New York
INDUSTRY KEYWORD: Health
Biotechnology
Hospitals
Pharmaceutical
Radiology
Research & Science
*** end of story ***
BTN.F trades @ new 52 wk high of 2.55euro(usd=3.07) on 63k shs....
beigledog: biph shldr mtg- u can attend without holding shs-
need 2 b holder of record to vote...
ENJOY....
BIPH Annual Mtg....
(BSNS WIRE) Biophan to Hold Annual Shareholder Meeting Wednesday, July 27; Co
pany Officers to Review Past Year's Milestone Achieve
Biophan to Hold Annual Shareholder Meeting Wednesday, July 27; Company Officers
o Review Past Year's Milestone Achievements and Business Initiatives for Coming
ear
Business Editors / Health/Medical Writers
ROCHESTER, N.Y.--(BUSINESS WIRE)--July 26, 2005--
Biophan Technologies, Inc. (OTCBB: BIPH), a developer of
next-generation biomedical technology, has announced that Company
officers will discuss its business and scientific milestones achieved
in the last year and planned initiatives, including potential
acquisitions and other significant steps, at its annual shareholders
meeting, scheduled to be held Wednesday, July 27, at the Lodge at
Woodcliff in Fairport, New York.
"I am looking forward to telling shareholders about the many
pivotal accomplishments that the scientists and businesspeople of
Biophan have achieved," said Michael Weiner, Biophan CEO. "We have
successfully executed our business strategy to commercialize our
advanced technologies, and we are building on these past milestones to
continue moving forward in our existing areas of business, as well as
expanding into exciting new markets where our expertise positions us
to develop new revenue streams."
Among the topics Biophan Management expects to discuss at the
annual shareholders meeting are the following:
-- Definitive Equity and License Agreements: The Company will
discuss business and technical details of its recently
executed definitive licensing and equity agreements with
leading medical device manufacturer Boston Scientific. The
money to be received from Boston Scientific under the
agreements will allow Biophan to file for listing on a major
stock exchange.
-- Continuing Developments in the Use of Magnetic Resonance
Imaging (MRI) Safe and Visualizable Implants and Surgical
Tools: Biophan has demonstrated methods for making medical
devices MRI safe and imageable. We anticipate adaptation and
growth in these important areas as more companies build MRI
safety and image visualization into forward product planning.
The Company is also developing enhanced contrast agents.
-- Intellectual Property Portfolio Growth: The Company's
intellectual property portfolio has grown to a total of 142
U.S. patents, licenses, or applications. Such patents include
unique technologies such as the tiny, nano-precise
MRI-compatible SQUIGGLE motor, held jointly by Biophan and
partner firm New Scale Technologies.
-- Completed and Planned Acquisitions: This year Biophan acquired
AMRIS GmbH, a company in Germany that develops advanced
solutions for effective imaging of medical devices with MRI
systems. AMRIS has since been reestablished as Biophan Europe.
The Company is exploring other potential strategic
acquisitions.
-- Expansion into Cardiovascular Device Market and Other
Strategic Business Initiatives: The Company is currently
reviewing several opportunities to broaden its activities from
its focus on medical device enhancements into the development
of new biomedical devices themselves. These include
cardiovascular therapeutic and diagnostic devices that the
Company feels would be marketable to its customer and prospect
base. At the shareholder meeting, Management will discuss
Biophan's positioning to develop new products with potential
for exclusive licensing in, and subsequent product development
and licensing out. Intellectual property, such as technology
solutions and patents, may be developed internally, through
joint ventures, licensed in, or purchased.
-- Expanded Strategic Partnerships: These include a cooperative
effort between Biophan's Nanolution division, which develops
advanced nanotechnology-based drug-delivery systems, and
NaturalNano Inc., a company developing naturally occurring
nanomaterials such as halloysite, a mineral with a rich
nanotube concentration. In a cooperative project, NaturalNano
(www.naturalnano.com) and Biophan's Nanolution division are
developing new drug-delivery capabilities, including extremely
long lasting drug-delivery coatings with the ability to
release drugs for a period of several years. Frost and
Sullivan has predicted that the convergence of biomedical
devices and pharmaceuticals represents a $40 billion market
potential. Among Biophan's technologies is "active drug
delivery," with controllable elution using "smart" coatings
which elute drugs when electromagnetic fields are presented at
a specific resonant frequency.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to
make biomedical devices safe and image compatible with the magnetic
resonance imaging (MRI) environment. The Company develops enabling
technologies for implanted medical systems such as pacemakers,
interventional surgical devices such as catheters and guidewires, and
devices such as stents to allow them to be safely and effectively
imaged under MRI. The technology is also being used to create MRI
contrast agents. Biophan is developing other applications, such as
drug delivery and power systems derived from body heat. Four Biophan
technologies include advances in nanotechnology and thin film
coatings. Committed to growth through innovation and developmental
leadership, Biophan and its licensors now hold a total of 142 U.S.
patents, licenses, or applications. This total includes 38 issued U.S.
patents, 9 recently-allowed applications that will issue as patents in
the near future, and 95 pending applications at various stages of
examination at the U.S. Patent and Trademark Office, plus
international applications. The patents cover areas including
nanotechnology (nanomagnetic particle coatings), radio frequency
filters, polymer composites, thermoelectric materials for batteries
generating power from body heat, and photonics. Biophan has joint
development and licensing agreements with Boston Scientific (NYSE: BSX
- News) and NASA's Ames Center for Nanotechnology. Biophan's goal is
to make all biomedical devices capable of safely and successfully
working with MRI, and delivering other technologies which will improve
quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute
forward-looking statements within the meaning of applicable securities
laws. These statements reflect what Biophan anticipates, expects, or
believes may happen in the future. Biophan's actual results could
differ materially from the outcome or circumstance expressed or
implied by such forward-looking statements as a result of a variety of
factors including, but not limited to: Biophan's ability to develop
its technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development
programs; the ability of Biophan to demonstrate the effectiveness of
its technology; the acceptance by the market of Biophan's technology
and products incorporating such technology, the ability of Biophan to
effectively negotiate and enter into contracts with medical device
manufacturers for the licensing of Biophan's technology; competition;
the ability of Biophan to raise capital to fund its operating and
research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future
operating performance, as well as other factors expressed from time to
time in Biophan's periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be read
in conjunction with Biophan's periodic filings with the SEC which are
incorporated herein by reference. The forward-looking statements
contained herein are made only as of the date of this press release,
and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or
circumstances.
KEYWORD: NORTH AMERICA NEW YORK UNITED STATES
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY HOSPITALS MEDICAL DEVICES PHARMACEUTICAL
ADIOLOGY RESEARCH & SCIENCE PROFESSIONAL SERVICES FINANCE
SOURCE: Biophan Technologies, Inc.
CONTACT INFORMATION:
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Jennifer Gould, 212-843-8037
*** end of story ***
*** end of story ***
Biophan, BPZ Energy, Chaparral Resources In New OTCBB Index (financialwire.net )
Jul 25, 2005 (financialwire.net via COMTEX) -- (FinancialWire) Biophan
Technologies (OTCBB: BIPH), BPZ Energy Inc (OTCBB: BPZI) and Chaparral Resources
Inc (OTCBB: CHAR) are three of the 30 companies being tracked by Public Company
Management Corporation (OTCBB: PUBC) in its new Over The Counter Bulletin Board
Index.
BTN.F trading +.01 to 2.44 euro(usd=2.95) on 9k shs.....
Biophan Technologies engages in the development of technologies that enable
biomedical devices to be safe and compatible for use in a magnetic resonance
imaging machine. Its biomedical devices include implantable medical devices,
such as pacemakers, as well as interventional devices, such as minimally
invasive surgical tools. It is based in West Henrietta, New York.
BPZ Energy operates as an oil and gas exploration and production company with
properties in northwest Peru and Ecuador. It has exclusive rights and license
agreements for oil and gas exploration and production covering approximately 2.7
million acres in four properties in northwest Peru. BPZ Energy also owns a
non-operating interest in a producing property in southwest Ecuador. The company
is based in Houston, Texas.
Chaparral Resources through its subsidiaries and joint ventures, engages in the
exploration, development, and production of oil and gas properties. The company
acquires and develops oil and gas projects, primarily fields with previously
discovered reserves. Chaparral focuses on the exploration and development of the
Karakuduk Field, a 16,900-acre oil field located in the central Asian Republic
of Kazakhstan. In addition, Chaparral also focuses its operations on other
independent countries within the former Soviet Union. The company is
headquartered in White Plains, New York.
This OTCBB Index has a 20-minute delayed financial data feed with key financial
and market information housed on PCMC's Web site. The index became live on July
15 and is available online at http://pcmc.stockgroup.com/pcmc30.asp . Further,
an interview on the construction and methodology of PCMC Bulletin Board 30 Index
is now available at http://www.publiccompanymanagement.com/PCMC-30/audio.html
The PCMC Bulletin Board 30 Index is comprised of 30 stocks that are selected
based on the following eight criteria:
(1) Three month average trade volume.
(2) Market capitalization.
(3) Historical stock price.
(4) Shares outstanding.
(5) Estimated float.
(6) Sales.
(7) Operating history.
(8) Industry/sector diversity.
The index includes the last trade price and daily volume and change data for
each of the included issues, weighted by industry segment to provide an
indicator overall performance of OTCBB traded stocks.
Over the past five years volume on the OTCBB has grown approximately ten-fold.
There was nearly a 300 percent increase from 1998 to 1999. Through the end of
April 2005, there were 77 billion shares traded on the OTCBB, according to the
OTC Journal. The PCMC Bulletin Board 30 Index(") is the only measurement of
performance of stocks traded in the Over the Counter Market. As of July 15,
2005, the composite of the PCMC Bulletin Board 30 Index(") has had a
year-to-date gain of 23 percent, with a three-month average total volume for the
index stocks of 5,974,400 shares during the same period. The 23 percent
year-to-date gain of the PCMC Bulletin Board 30 Index(") sharply outperformed
other comparable indexes during the same period, such as the S&P 500 (2.15
percent gain), Dow Jones 30 (1.32% loss), Russell 2000 Index (3.64% gain), and
Russell MicroCap Index (0.53% loss).
PCMC Bulletin Board 30 Index(") Key Statistics (7/15/05):
Average Stock Market Cap: $193,215,955
Total Index 30 Market Cap: $5,796,478,650
Average Stock Price: $5.94
Total Index Value: 178.25
Daily Average Stock Volume: 216,209
Daily Total Index Volume: 6,486,269
3-mo Average Volume of Stocks: 199,147
3-mo Total Volume of Index: 5,974,400
PCMC 30 One-Month Return: 5.88%
PCMC 30 Three-Month Return: 9.42%
PCMC 30 Year-To-Date Return: 23.05%
Number of Industries: 7
Number of Sectors: 23
Total index value is the summation of the 30 stock prices.
Public Company Management Corp. is enrolled in Investrend Research's unique and
pioneering professional analyst program, which facilitates independent analysts
to provide financial coverage for shareholders and investors in companies that
otherwise would have little or no analyst following. Enrollment in
standards-based research is an important measure of a company's commitment to
transparency and Good Governance.
On December 13, 2004, Investrend Research analyst Kipley Lytel, CFA, rated the
company a "Speculative Buy / 4," with a target valuation of $2.30. On May 31,
2005, Lytel reiterated his rating and upgraded his target to $2.80, stating that
the company's results had considerably exceeded the analyst's expectations.
The Investrend Research program is the largest in the world and includes a
number of safeguards to reduce or eliminate conflict. These systems, including
media coverage and endorsements, may be accessed at
http://www.investrendresearch.com
Investrend Research subscribes to the "Standards for Independent Research
Providers" at http://www.firstresearchconsortium.com, and adheres to the
Guidelines for independent providers jointly endorsed by the National Investor
Relations Institute (http://www.niri.org) and the CFA Institute
(http://www.cfainstitute.org) .
Buyside Magazine has stated that Investrend Research "remains in the vanguard of
both standards and independence." ODwyerPR has cited Investrend Research as
"exceeding the standards of CFAI-NIRI." The CFA Magazine, citing Investrend and
its affiliates as having "strict rules about compensation and full disclosure,"
which "should go a long way towards ensuring objectivity," said "issuer-paid
research is here to stay." Investrend has been cited by the Dow Jones Newswires,
Financial Mail, Shareholder Value, and NIRI's "IR Update," which stated that
Investrend "accomplishes the goal and more." Investrend's model has been
endorsed by the New York Times, former SEC Chair Arthur Levitt and shareholders
themselves, 70.9% of whom said in a survey at InvestoPedia, that a company that
enrolls for "legitimate fee-based research is making a positive statement about
its investment potential." A survey at Charles Schwab & Co. revealed that 78% of
active shareholders now "value research from independent firms over analysts by
Wall Street firms with financial ties to the companies they are rating."
Enrollment fees for the Wall Street research platform are $39,840, which is
being paid by the company. There are never any fees associated with
FinancialWire, which independently covers a wide range of corporate news,
including but not limited to those that are or have been enrolled in
Investrend's platforms.
Complete information about any company enrolled in an Investrend shareholder
empowerment platform, including those of its affiliates and independent analysts
and webcasters, including disclosures and disclaimers, is available at the
company's InvestorPower page at
http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report
and press release, and investors are advised to read those disclosures carefully
before trading in the equities of any enrolled company.
For up-to-the-minute news, features and links click on
http://www.financialwire.net
FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
http://www.investrend.com/contact.asp
The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268
URL: http://www.financialwire.net
(C) 2005 financialwire.net, Inc. All rights reserved.
-0-
*** end of story ***
BIPH: TechStockReview.com: Opening Bell Report & Alerts - Friday, July 22 ISON, BIPH, MDTV, CAFE ( M2 PRESSWIRE )
B: TechStockReview.com: Opening Bell Report & Alerts - Friday, July 22 ISON, BIP
, MDTV, CAFE ( M2 PRESSWIRE )
Arlington, Texas, Jul 22, 2005 (M2 PRESSWIRE via COMTEX) -- Featured stock on
TechStockReview.com Opening Bell Report: Isonics (Nasdaq: ISON) Names Veteran
Fortune 500 Investment Banker and Corporate Executive Richard Hagman to Board of
Directors, Biophan (OTCBB: BIPH) Announces Online Availability of ValueRich
Magazine Article on Company's Advanced Biomedical Technology, MDU (OTCBB: MDTV)
Communications Announces Former DIRECTV Executive Vice President Steve Cox and
Venture Capital Firm Founder/Manager Carolyn Howard to Join Board of Directors ,
and (Nasdaq: CAFE) CORRECTION: Host America gets SEC Request for Documents, not
Subpoenaed.
Isonics Corporation (ISON), committed to the development of next-generation
technology for the homeland security and semiconductor markets, has named
Fortune 500 executive and veteran investment banking professional Dr. Richard
Hagman to the Company's Board of Directors and as chair of the Board's Audit
Committee. Dr. Hagman has more than 20 years of corporate management and
top-tier executive experience in several Fortune 500 companies. He was Chairman
and CEO of WENR Corp. (formerly Western Energy Inc.), and served as Vice
President and Corporate Officer of Cyprus Amax Minerals Co. Dr. Hagman also held
senior investment and government affairs positions for such companies as Amoco
Corp. For the full story go: www.TechStockReview.com and scroll to the bottom of
the page to: Isonics Names Veteran Fortune 500 Investment Banker and Corporate
Executive Richard Hagman to Board of Directors; Hagman Brings Company Extensive
Background in Capital Sourcing, Mergers & Acquisitions, and Corporate
Operations.
Biophan Technologies, Inc. (BIPH), a developer of next-generation biomedical
technology, announced Thursday the online availability of an in-depth feature
story illustrated with high-quality explanatory graphics about the Company's
advanced biotechnology innovations, which was recently published in the Summer
2005 issue of ValueRich Magazine. The article discusses Biophan's comprehensive
solutions to make medical devices and surgical tools safe and image-compatible
with Magnetic Resonance Imaging (MRI) systems, and provides insight into the
global marketplace potential for such solutions. "Over $12 billion worth of
medical devices shipped annually are not safe for use with MRI and/or are not
imageable," the article states. "Due to safety concerns including heating of
devices and metal wire leads which can cause tissue damage, most MRI imaging
centers currently refuse patients with pacemakers and other implanted medical
devices, meaning they are denied access to one of the most important diagnostic
tools in medicine. Rather than accepting this as an unavoidable limitation of
the technology, Biophan set out to solve the problem."
MDU Communications International, Inc. (MDTV), a leading end-to-end provider of
DIRECTV digital satellite television programming, high-speed Internet and other
premium communication and information services to the residential multi-dwelling
unit ("MDU") market, is pleased to announce that effective immediately, Steven
J. Cox and Carolyn C. Howard have accepted appointments to its Board of
Directors. Mr. Cox brings over ten years of DIRECTV growth experience to the
Company. Ms. Howard brings over twenty years of executive and financial market
experience to the Company and will serve on its Audit Committee as the
independent financial expert.
Host America Corp. (CAFe) said Wednesday that the Securities and Exchange
Commission has asked for documents and related information in connection with
the company's July 12 press release and related trading of their stock. Host
America said that day that it will start surveying 10 Wal-Mart Stores Inc.
stores in the Southwest in preparation for the installation of its
LightMasterPlus system on the fluorescent lighting in each store. The company
said it is cooperating with the SEC request. (Corrects the headline to reflect
that the company was not subpoenaed by the SEC.)
About TechStockReview.com: a leading destinations on the internet for
information on small and micro cap technology companies. Companies interested in
our services may contact our Publisher, Michael Hammersley, to discuss featuring
a company on our web sites.
Disclosure: Tech Stock Review, LLC is not a registered investment advisers or
broker/dealers. Tech Stock Review, LLC makes no recommendation that the purchase
of securities of companies profiled in this website is suitable or advisable for
any person or that an investment such securities will be profitable.
CONTACT: Michael A. Hammersley Tel: +1 682 560 5600 e-mail:
editor@techstockreview.com
M2 Communications Ltd disclaims all liability for information provided within M2
PressWIRE. Data supplied by named party/parties. Further information on M2
PressWIRE can be obtained at http://www.presswire.net on the world wide web.
Inquiries to info@m2.com.
(C)1994-2005 M2 COMMUNICATIONS LTD
-0-
*** end of story ***
B: Biophan Announces Online Availability of ValueRich Magazine Article on Company's Advanced Biomedical Technology Article Features Proprietary Biophan Nanotechn
logy Solutions to Make Medical Devices Safe and Compatible with MRI Systems
in Frankurt, BIPH trading +.10 to 2.42euro(usd=2.95) on 17k shs..
ROCHESTER, N.Y., Jul 21, 2005 (BUSINESS WIRE) -- Biophan Technologies, Inc.
(OTCBB: BIPH), a developer of next-generation biomedical technology, announced
today the online availability of an in-depth feature story illustrated with
high-quality explanatory graphics about the Company's advanced biotechnology
innovations, which was recently published in the Summer 2005 issue of ValueRich
Magazine.
The article discusses Biophan's comprehensive solutions to make medical devices
and surgical tools safe and image-compatible with Magnetic Resonance Imaging
(MRI) systems, and provides insight into the global marketplace potential for
such solutions. "Over $12 billion worth of medical devices shipped annually are
not safe for use with MRI and/or are not imageable," the article states. "Due to
safety concerns including heating of devices and metal wire leads which can
cause tissue damage, most MRI imaging centers currently refuse patients with
pacemakers and other implanted medical devices, meaning they are denied access
to one of the most important diagnostic tools in medicine. Rather than accepting
this as an unavoidable limitation of the technology, Biophan set out to solve
the problem."
Biophan recently signed a landmark agreement to license some of its proprietary
technologies to leading medical device manufacturer, Boston Scientific (NYSE:
BSX). Biophan also is in discussions with other major manufacturers.
To view the ValueRich article, please visit
http://www.biophan.com/articles/0705_ValueRich5.pdf
About ValueRich Magazine
ValueRich Magazine is a finance and luxury lifestyle magazine with a circulation
of fifty eight thousand readers. It is sent directly to the chief executives of
publicly traded companies in the United States as well as investment bankers,
venture capitalists, and qualified private investors in both the United States
and Europe. It reaches a very specific and affluent group of readers who travel
regularly and are not easily reached through other means. Additionally,
ValueRich hosts conventions each year in New York and Palm Beach, Florida.
Please visit www.valuerichonline.com for more information.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make
biomedical devices safe and image compatible with the magnetic resonance imaging
(MRI) environment. The Company develops enabling technologies for implanted
medical systems such as pacemakers, interventional surgical devices such as
catheters and guidewires, and devices such as stents to allow them to be safely
and effectively imaged under MRI. The technology is also being used to create
MRI contrast agents. Biophan is developing other applications, such as drug
delivery and power systems derived from body heat. Four Biophan technologies
include advances in nanotechnology and thin film coatings. Committed to growth
through innovation and developmental leadership, Biophan and its licensors now
hold a total of 142 U.S. patents, licenses, or applications. This total includes
38 issued U.S. patents, 9 recently-allowed applications that will issue as
patents in the near future, and 95 pending applications at various stages of
examination at the U.S. Patent and Trademark Office, plus international
applications. The patents cover areas including nanotechnology (nanomagnetic
particle coatings), radio frequency filters, polymer composites, thermoelectric
materials for batteries generating power from body heat, and photonics. Biophan
has joint development and licensing agreements with Boston Scientific (NYSE: BSX
- News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all
biomedical devices capable of safely and successfully working with MRI, and
delivering other technologies which will improve quality of life. For more
information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking
statements within the meaning of applicable securities laws. These statements
reflect what Biophan anticipates, expects, or believes may happen in the future.
Biophan's actual results could differ materially from the outcome or
circumstance expressed or implied by such forward-looking statements as a result
of a variety of factors including, but not limited to: Biophan's ability to
develop its technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development programs; the
ability of Biophan to demonstrate the effectiveness of its technology; the
acceptance by the market of Biophan's technology and products incorporating such
technology, the ability of Biophan to effectively negotiate and enter into
contracts with medical device manufacturers for the licensing of Biophan's
technology; competition; the ability of Biophan to raise capital to fund its
operating and research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in Biophan's
periodic filings with the Securities and Exchange Commission (the "SEC"). As a
result, this press release should be read in conjunction with Biophan's periodic
filings with the SEC which are incorporated herein by reference. The
forward-looking statements contained herein are made only as of the date of this
press release, and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Biophan Technologies, Inc.
CONTACT: Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Jennifer Gould, 212-843-8037
Copyright Business Wire 2005
-0-
KEYWORD: United States
Germany
Europe
North America
New York
INDUSTRY KEYWORD: Health
Biotechnology
Hospitals
Medical Devices
Radiology
Research & Science
Professional Services
Finance
*** end of story ***
BIPH: fwiw - BTN.F is +.08 to 2.18 euro(usd=2.66)
2.15/2.19 euro
TINY: continues brk/out-+.35 to 13.59..eom
BIPH Annual Rpt-- Biophan Announces Online Availability of Annual Report Detailing Corporate Milestones, Growth, and Licensing Strateg
B: Biophan Announces Online Availability of Annual Report Detailing Corporate Mi
estones, Growth, and Licensing Strategy; Report for Year Ended February 28, 2005
Now Available on Company Website
ROCHESTER, N.Y., Jul 11, 2005 (BUSINESS WIRE) -- Biophan Technologies, Inc.
(OTCBB: BIPH), a developer of next-generation biomedical technology, has posted
its 2005 Annual Report on the Biophan website, making available the details of
its key technological achievements and business activities for the year ended
February 28, 2005.
The report provides a comprehensive picture of the fiscal year's accomplishments
as Biophan continues to execute its strategy to deliver proprietary technologies
that improve life-saving and life-enhancing medical devices. The report includes
a color wrap-around overview of the Company and its technologies. A printed copy
of the Annual Report has been mailed to all shareholders of record.
"This year has been more exciting and eventful for Biophan than any previous
year," wrote CEO Michael Weiner and Chairman of the Board Guenter H. Jaensch, in
the report's Letter to Shareholders. "We are in a period of significant growth,
and we will continue to forge ahead with plans for continued progress this year,
and in the years to come."
"We have expanded the base of technologies we are developing, to reach even
broader markets with the potential for significant future revenue streams for
Biophan," Mr. Weiner and Dr. Jaensch added.
These new technologies include Biophan's initiatives within its Nanolution
division to develop technologies for improved, "active drug delivery" using
novel nanomaterials, allowing Biophan to participate in the $40 billion drug
delivery market.
Among the annual report's highlights is the dramatic growth of the Company's
intellectual property portfolio during the year ended in February of 2005. "We
have greatly broadened our technology base, more than doubling the number of US
patents in our patent portfolio from 60 to 127 in the last year, and we now have
46 issued and pending international patents. The number of issued US patents has
increased from 9 to 36. We expect these numbers to continue to grow," Mr. Weiner
and Dr. Jaensch wrote.
In the months after the period covered by the report, the Company has indeed
continued to expand its intellectual property portfolio, and holds a total of
140 U.S. patents, licenses, or applications, of which 38 have issued, and 9
additional have been allowed (meaning they will soon issue).
The report further describes Biophan's progress in its strategy to generate
significant revenues through licensing of its patents and intellectual property.
It describes collaborative agreements with complementary companies and strategic
partners, including the joint development agreement with Boston Scientific, one
of the major medical device manufacturers. That agreement led to Biophan's
recently executed licensing and investment agreements with Boston Scientific.
Under the agreements, Boston Scientific has licensed a number of Biophan's
next-generation proprietary biomedical technologies, for a $750,000 advance
license fee, plus milestone payments, annual minimums, and royalties with the
potential for significant multi-million dollar revenues. In addition, Boston
Scientific is scheduled to make a $5 million equity investment in Biophan by
August 15, 2005.
Biophan is committed to solving critical safety and image compatibility problems
many medical devices suffer from when in Magnetic Resonance Imaging (MRI)
environments. These include undesirable heating of implanted medical devices or
surgical tools, as well as potentially fatal induced voltages in devices such as
pacemakers, defibrillators, and neuro-stimulators. Biophan has created a broad
"patent thicket" covering these solutions, to safeguard its competitive lead and
anticipated revenue streams.
Research and development progress noted in the Annual Report include the
following achievements and milestones.
-- Demonstration of technology allowing the visualization of restenosis within
stents using MRI and non-invasive means, covered by Biophan's intellectual
property.
-- Acquisition of an MRI-visible vena cava filter, designed to trap circulating
blood clots, plaque, or other materials that can cause lung embolisms; and
enabling visualizing the device before extracting the device, avoiding potential
lethal release of the trapped materials.
-- Licensing of exclusive medical rights to a line of unique MRI-safe and
image-compatible non-magnetic Squiggle(TM) motors;
-- Formation of the Nanolution drug delivery division to develop unique
nanotechnology-based drug-elution and drug delivery systems; including "active
drug delivery," on demand, using non-invasive energy activating materials with
no electrical components.
-- Progress in development of a biothermal power source that generates
electricity from body heat to run implantable medical devices; being
co-developed with NASA's Ames Center for Nanotechnology, in Moffet Field,
California.
Leveraging strategic relationships is also vital to Biophan's mission, to create
new sales channels and joint development projects. Progress noted in this area
include:
-- Signing of a Term Sheet with medical device manufacturer Boston Scientific,
further validating Biophan's innovative technologies; (which subsequently
converted to documents executed on June 30, 2005).
-- Acquisition of a 51% interest in the firm, TE Bio LLC, developer of the
implantable biothermal power source;
-- Completion of the acquisition of a majority interest in aMRIs GmbH, a leading
technology company, based in Germany, with important MRI visualization
technology and a renowned medical industry staff. The acquisition brought 15
additional issued and pending patents; aMRIs was renamed Biophan Europe and is
expanding operations and affiliations with other leaders in the medical device
arena.
-- Establishment of a joint development agreement with the NASA Ames Research
Center for building prototypes of the biothermal power source.
To view the report, visit http://www.biophan.com, and select the "Investor
Information" option on the home page. Then select "2005 Annual Report" from the
choices on the left hand side of the page.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make
biomedical devices safe and image compatible with the magnetic resonance imaging
(MRI) environment. The Company develops enabling technologies for implanted
medical systems such as pacemakers and interventional surgical devices such as
catheters, guidewires, stents, and other implants to allow them to be safely and
effectively imaged under MRI. The technology is also being used to create MRI
contrast agents, and has expanded to include other applications, such as drug
delivery and power systems derived from body heat. Four Biophan technologies
include advances in nanotechnology and thin film coatings. Committed to growth
through innovation and developmental leadership, Biophan and its licensors now
hold a total of 140 U.S. patents, licenses, or applications. This total includes
38 issued U.S. patents, 9 recently-allowed applications that will issue as
patents in the near future, and 93 pending applications at various stages of
examination at the U.S. Patent and Trademark Office, plus international
applications. The patents cover areas including nanotechnology (nanomagnetic
particle coatings), radio frequency filters, polymer composites, thermoelectric
materials for batteries generating power from body heat, and photonics. Biophan
has joint development and licensing agreements with Boston Scientific (NYSE: BSX
- News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all
biomedical devices capable of safely and successfully working with MRI, and
delivering other technologies which will improve quality of life. For more
information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking
statements within the meaning of applicable securities laws. These statements
reflect what Biophan anticipates, expects, or believes may happen in the future.
Biophan's actual results could differ materially from the outcome or
circumstance expressed or implied by such forward-looking statements as a result
of a variety of factors including, but not limited to: Biophan's ability to
develop its technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development programs; the
ability of Biophan to demonstrate the effectiveness of its technology; the
acceptance by the market of Biophan's technology and products incorporating such
technology, the ability of Biophan to effectively negotiate and enter into
contracts with medical device manufacturers for the licensing of Biophan's
technology; competition; the ability of Biophan to raise capital to fund its
operating and research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in Biophan's
periodic filings with the Securities and Exchange Commission (the "SEC"). As a
result, this press release should be read in conjunction with Biophan's periodic
filings with the SEC which are incorporated herein by reference. The
forward-looking statements contained herein are made only as of the date of this
press release, and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Biophan Technologies, Inc.
CONTACT: Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Jennifer Gould, 212-843-8037
Copyright Business Wire 2005
-0-
KEYWORD: United States
Germany
Europe
North America
New York
INDUSTRY KEYWORD: Health
Biotechnology
Hospitals
Medical Devices
Radiology
Research & Science
Professional Services
Finance
*** end of story ***
Lonestar:
this AM downward spike was to put in
a bottom & clean up the charts
4 the next leg up...
probably just a blip in the
chart for "investors"....
SEC Form 8-K/A: Biophan Details Technology License and Investment Agreements with Boston Scientific in SEC Form 8-K/A Provisions Inc
B: Biophan Details Technology License and Investment Agreements with Boston Scie
tific in SEC Form 8-K/A Provisions Include $5 Million Equity Investment by Bosto
Scientific, Royalties and Milestone Payments for Proprietary Technologies
excerpt: The technology license agreement........ to make implantable medical devices and "surgical tools" safe &/or image compatible in Magnetic Imaging Resonance (MRI) systems...
ROCHESTER, N.Y., Jul 08, 2005 (BUSINESS WIRE) -- Biophan Technologies, Inc.
(OTCBB: BIPH), a developer of next-generation biomedical technology, further
detailed the terms of its technology licensing and equity agreements with
leading medical device manufacturer Boston Scientific Corporation (NYSE: BSX) in
an SEC Form 8-K/A filed today.
The technology license agreement has a number of provisions, including the
granting of various rights to commercially implement a number of Biophan's
patented solutions to make implantable medical devices and surgical tools safe
and/or image-compatible in Magnetic Resonance Imaging (MRI) systems. The
agreement grants Boston Scientific various exclusive and non-exclusive licenses,
for certain products, to a number of Biophan's proprietary technologies, plus
sublicensing rights for the sale of commercial products that are based on the
licensed technologies.
"We believe these agreements with Boston Scientific represent the next
significant step toward the creation of medical devices that are MRI-safe and
image compatible," said Biophan CEO Michael Weiner. "Through use of our
proprietary technology, leading medical device manufacturers will have the
ability to produce and market medical devices that offer critical advantages of
MRI safety and MRI image compatibility. These agreements are an important
milestone along that path."
Under the terms of the agreements, Boston Scientific will pay Biophan an upfront
license fee of $750,000, plus annual license maintenance fees. Boston Scientific
will also make milestone payments for the launch of commercial products based on
the licensed technologies, and Biophan will receive royalties on the sale of
products that employ the licensed technologies.
Boston Scientific is also acquiring $5 million of Biophan common stock, priced
at a 10% premium over the average of the closing price for the 30 calendar-day
period preceding the closing. Funding under both agreements is expected to occur
following confirmation of paperwork related to our recent acquisitions.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make
biomedical devices safe and image compatible with the magnetic resonance imaging
(MRI) environment. The Company develops enabling technologies for implanted
medical systems such as pacemakers and interventional surgical devices such as
catheters, guidewires, stents, and other implants to allow them to be safely and
effectively imaged under MRI. The technology is also being used to create MRI
contrast agents, and has expanded to include other applications, such as drug
delivery and power systems derived from body heat. Four Biophan technologies
include advances in nanotechnology and thin film coatings. Committed to growth
through innovation and developmental leadership, Biophan and its licensors now
hold a total of 140 U.S. patents, licenses, or applications. This total includes
38 issued U.S. patents, 9 recently-allowed applications that will issue as
patents in the near future, and 93 pending applications at various stages of
examination at the U.S. Patent and Trademark Office, plus international
applications. The patents cover areas including nanotechnology (nanomagnetic
particle coatings), radio frequency filters, polymer composites, thermoelectric
materials for batteries generating power from body heat, and photonics. Biophan
has joint development and licensing agreements with Boston Scientific (NYSE: BSX
- News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all
biomedical devices capable of safely and successfully working with MRI, and
delivering other technologies which will improve quality of life. For more
information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking
statements within the meaning of applicable securities laws. These statements
reflect what Biophan anticipates, expects, or believes may happen in the future.
Biophan's actual results could differ materially from the outcome or
circumstance expressed or implied by such forward-looking statements as a result
of a variety of factors including, but not limited to: Biophan's ability to
develop its technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development programs; the
ability of Biophan to demonstrate the effectiveness of its technology; the
acceptance by the market of Biophan's technology and products incorporating such
technology, the ability of Biophan to effectively negotiate and enter into
contracts with medical device manufacturers for the licensing of Biophan's
technology; competition; the ability of Biophan to raise capital to fund its
operating and research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in Biophan's
periodic filings with the Securities and Exchange Commission (the "SEC"). As a
result, this press release should be read in conjunction with Biophan's periodic
filings with the SEC which are incorporated herein by reference. The
forward-looking statements contained herein are made only as of the date of this
press release, and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Biophan Technologies, Inc.
CONTACT: Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Jennifer Gould, 212-843-8037
Copyright Business Wire 2005
-0-
KEYWORD: United States
North America
New York
INDUSTRY KEYWORD: Technology
Other Technology
Health
Biotechnology
Hospitals
Infectious Diseases
Medical Devices
Oncology
Pharmaceutical
Radiology
Research & Science
Professional Services
Finance
SUBJECT CODE: Contract/Agreement
*** end of story ***
Jul 07, 2005 (BUSINESS WIRE) -- Biophan Technologies, Inc.
(OTCBB: BIPH), a developer of next-generation medical technology, announced today that its biothermal power source for implantable devices has been recognized as a "Best of the Best" invention by Nanotech Briefs magazine as part of its first annual Nano 50 Awards contest to recognize superior scientific
achievement and innovation. Developed by Biophan subsidiary TE Bio, the biothermal power source converts body heat into electricity to power implantablemedical devices.
"This latest validation of our biothermal power source further distinguishes
Biophan's groundbreaking work in the field of nanotechnology and thermoelectric
materials by a panel of expert judges," said Biophan CEO Michael Weiner. "It's
always gratifying when our advanced solutions receive outside recognition for
their innovation, functionality, and potential for impact on biomedical and
other market sectors. We are proud of this recognition and we look forward to
formally accepting the Nano 50 "Best of the Best" honor at the Nanotech Briefs
awards ceremony."
The nominations for the Nano 50 were judged by a panel of nanotechnology and
MEMS experts. The technologies, products, and innovators receiving the 50
highest scores were named winners of the Nano 50 "Best of the Best" awards.
Presented by Nanotech Briefs magazine, a digital publication from the publishers
of NASA Tech Briefs, the Nano 50 recognizes the top 50 technologies, products,
and innovators that have significantly impacted, or are expected to impact, the
state of the art in nanotechnology.
Based on innovations in thermoelectric materials, Biophan's biothermal power
source converts thermal energy produced naturally by the human body into usable
electrical energy. These thermoelectric materials are special types of
semiconductors that produce electricity when there is a temperature difference
between one side of the material and the other. These materials have been used
to generate electricity on spacecraft, such as the Voyager space probe. The
power they generate can be used to directly power implanted devices such as
pacemakers, neurostimulators, biosensors, drug pumps, lab-on-a-chip devices,
pain devices, and other implantable devices, or to trickle-charge batteries for
devices with high discharge requirements, such as implantable cardiac
defibrillators (ICDs) and drug pumps.
Biophan's nanotechnology applications span a range of existing and emerging
multi-billion-dollar markets in biosciences and healthcare. The biothermal power
source was developed by Biophan research and development subsidiary TE-Bio.
Biophan's TE-Bio subsidiary has an agreement with NASA for characterization and
joint development of high-density, nanoengineered thermoelectric materials for
use with implantable medical devices. Research is being jointly conducted by
Biophan and NASA personnel at the NASA Ames Research Center for Nanotechnology
in Moffett Field, CA.
The Nano 50 will be presented at a special awards dinner during the NASA Tech
Briefs Nano 2005 conference in Boston, November 11-12, 2005.
About Nanotech Briefs
Nanotech Briefs, launched in January 2004, is a digital (PDF format) magazine
from the publishers of NASA Tech Briefs - the country's largest-circulation
design engineering magazine - that provides the best of government, industry and
university nanotech innovations with real-world applications in areas such as
electronics, materials, sensors, manufacturing, biomedical, optics/photonics,
and aerospace/defense. Nanotech Briefs is the first small-tech publication
specifically for design engineers who are designing tomorrow's nanotech products
today. For more information, please visit www.nanotechbriefs.com.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make
biomedical devices safe and image compatible with the magnetic resonance imaging
(MRI) environment. The Company develops enabling technologies for implanted
medical systems such as pacemakers and interventional surgical devices such as
catheters, guidewires, stents, and other implants to allow them to be safely and
effectively imaged under MRI. The technology is also being used to create MRI
contrast agents, and has expanded to include other applications, such as drug
delivery and power systems derived from body heat. Four Biophan technologies
include advances in nanotechnology and thin film coatings. Committed to growth
through innovation and developmental leadership, Biophan and its licensors now
hold a total of 140 U.S. patents, licenses, or applications. This total includes
38 issued U.S. patents, 9 recently-allowed applications that will issue as
patents in the near future, and 93 pending applications at various stages of
examination at the U.S. Patent and Trademark Office, plus international
applications. The patents cover areas including nanotechnology (nanomagnetic
particle coatings), radio frequency filters, polymer composites, thermoelectric
materials for batteries generating power from body heat, and photonics. Biophan
has joint development and licensing agreements with Boston Scientific (NYSE:BSX)
and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all
biomedical devices capable of safely and successfully working with MRI, and
delivering other technologies which will improve quality of life. For more
information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking
statements within the meaning of applicable securities laws. These statements
reflect what Biophan anticipates, expects, or believes may happen in the future.
Biophan's actual results could differ materially from the outcome or
circumstance expressed or implied by such forward-looking statements as a result
of a variety of factors including, but not limited to: Biophan's ability to
develop its technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development programs; the
ability of Biophan to demonstrate the effectiveness of its technology; the
acceptance by the market of Biophan's technology and products incorporating such
technology, the ability of Biophan to effectively negotiate and enter into
contracts with medical device manufacturers for the licensing of Biophan's
technology; competition; the ability of Biophan to raise capital to fund its
operating and research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in Biophan's
periodic filings with the Securities and Exchange Commission (the "SEC"). As a
result, this press release should be read in conjunction with Biophan's periodic
filings with the SEC which are incorporated herein by reference. The
forward-looking statements contained herein are made only as of the date of this
press release, and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Biophan Technologies, Inc.
CONTACT: Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Jennifer Gould, 212-843-8037
Copyright Business Wire 2005
-0-
KEYWORD: United States
North America
New York
INDUSTRY KEYWORD: Health
Biotechnology
Hospitals
Medical Devices
Oncology
Pharmaceutical
Radiology
Research & Science
Professional Services
Finance
SUBJECT CODE: Product/Service
*** end of story ***
(financialwire.net via COMTEX)7/05/2005- Biophan Technologies Inc. (OTCBB: BIPH) gained 10% Friday on volume trading at
1,633,624, which is 2 times the average volume of 715,598 to close at $2.87.
Biophan is enrolled in Beacon Equity Research's professional analyst program,
which facilitates independent analysts to provide financial coverage for
shareholders and investors in companies that otherwise would have little or no
analyst following. Enrollment in standards-based research is an important
measure of a company's commitment to transparency and Good Governance.
On March 14, 2005, Beacon analyst Shailesh Dhuri, CFA, issued a preliminary
Research Note, and is preparing a comprehensive report.
Beacon Equity Research, LLC is a fee-based, comprehensive investment research
firm, focusing primarily on the underserved small-cap sector. All Beacon
analysts are seasoned industry professionals and adhere to the CFA Institute's
(CFAI) stringent ethics and standards of practice guidelines. Beacon Research
does not have any investment banking relationships with any of the companies
covered. All analysts are compensated prior to performing their investment
research and are not compensated in any way based on the future performance of
the equities they follow.
Both Beacon Equity Research and Investrend Research subscribe to the "Standards
for Independent Research Providers" at http://www.firstresearchconsortium.com,
and adhere to the Guidelines for independent providers jointly endorsed by the
National Investor Relations Institute (http://www.niri.org) and the CFA
Institute (http://www.cfainstitute.org)
Beacon is being compensated $18,000 for a year's coverage.
The Dow Jones Newswires has stated that independent research has been growing in
credibility over the past 18 months, specifically citing Investrend Research,
and the New York Times has reported a survey by Charles Schwab & Co. reveals an
astonishing 78 percent of active stockholders now "value research from
independent firms over analysis by Wall Street firms with financial ties to the
companies they are rating." A survey at Investopedia reveals that 74.7% of
investors say that "legitimate fee-based research is objective and useful," and
70.9% say that a company that enrolls for "legitimate fee-based research is
making a positive statement about its investment potential."
There are never any fees associated with FinancialWire, which independently
covers a wide range of corporate news, including but not limited to those that
are or have been enrolled in Investrend's platforms.
Complete information about any company enrolled in an Investrend shareholder
empowerment platform, including those of its affiliates and independent analysts
and webcasters, including disclosures and disclaimers, is available at the
company's InvestorPower page at
http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report
and press release, and investors are advised to read those disclosures carefully
before trading in the equities of any enrolled company.
For up-to-the-minute news, features and links click on
http://www.financialwire.net
FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
http://www.investrend.com/contact.asp
The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268
URL: http://www.financialwire.net
(C) 2005 financialwire.net, Inc. All rights reserved.
-0-
*** end of story ***
on Thursday, August Gold settled +3.50 to close @ 443.20.
gold continues to benefit mainly from bullish technicals,
the recent decoupling from eur/usd, eurozone disharmony,
+er oil prices,& +ed focus on inflation hedge.
a test of the 3/11 high of 447.60(august gold)
is likely, with support holding @ 434.50 - 430.
longer term, 470 remains the next objective...
august gold +4.50 to new reaction high @ 444.20..eom
august gold settled down .80 to 439.70.
appears to b waiting for a resolution of the usd & bonds.
wud continue to trade long above 432(stop raised from 430.10
to 432)..
COMTEX B: Biophan CEO to Present Drug Delivery Technologies at the Pharma Finance 2005 Conference in Rome; CEO to Outline Business and Growth Plan Through Commercialization of Intellectual Property Portfolio...
excerpt-"We are pleased to see that a number of important pharmaceutical companies are attending. We have several one-on-one meetings with these companies at the conference."
ROCHESTER, NY, Jun 23, 2005 (BUSINESS WIRE) -- Biophan Technologies, Inc.
(OTCBB: BIPH), a developer of next-generation medical technology, will present
an overview of its proprietary drug delivery technologies at the Pharma Finance
2005 conference at the Jolly Hotel in Rome, Italy, on June 23-24.
"The Pharma Finance conference in Rome provides us with a valuable opportunity
for high level exposure for our drug delivery technologies," said Mr. Weiner.
"We are pleased to see that a number of important pharmaceutical companies are
attending. We have several one-on-one meetings with these companies at the
conference."
"Biophan's drug delivery technology arose from our work to fine tune
nanomagnetic nanoparticles so they resonate at a specific frequency," Mr. Weiner
explained. "The technology was originally developed in support of our work on
safety and visualization of medical devices. The ability to fine tune particles
to specific frequencies led to the concept of using the nanomagnetic particles
to selectively control drug release as well as to reduce the toxicity of the
drugs."
Details on the drug delivery technology can be viewed at
http://www.biophan.com/products.php by selecting Drug Delivery from the menu.
About Pharma Finance 2005
The Pharma Finance 2005 Conference, organized by the Milano Group, is scheduled
to be held June 23-24 at the Jolly Hotel - Villa Carpegna in Rome, Italy. It
will bring together a range of emerging growth biotechnology companies with
cutting edge, innovative research vehicles and life-enhancing product pipelines.
Participating companies represent an array of therapeutic topics including
oncology, cardiovascular disease, central nervous system disorders, infectious
diseases and medical device technology. The event will expose companies to
institutional investors, venture capitalists, senior corporate executives and
experts from the scientific and medical communities. For more information, visit
www.milanogroup.com.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make
biomedical devices safe and image compatible with the magnetic resonance imaging
(MRI) environment. The Company develops enabling technologies for implanted
medical systems such as pacemakers and interventional surgical devices such as
catheters, guidewires, stents, and other implants to allow them to be safely and
effectively imaged under MRI. The technology is also being used to create MRI
contrast agents, and has expanded to include other applications, such as drug
delivery and power systems derived from body heat. Four Biophan technologies
include advances in nanotechnology and thin film coatings. Committed to growth
through innovation and developmental leadership, Biophan and its licensors now
hold a total of 140 U.S. patents, licenses, or applications. This total includes
38 issued U.S. patents, 9 recently-allowed applications that will issue as
patents in the near future, and 93 pending applications at various stages of
examination at the U.S. Patent and Trademark Office, plus international
applications. The patents cover areas including nanotechnology (nanomagnetic
particle coatings), radio frequency filters, polymer composites, thermoelectric
materials for batteries generating power from body heat, and photonics. Biophan
has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's
Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices
capable of safely and successfully working with MRI, and delivering other
technologies which will improve quality of life. For more information, please
visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking
statements within the meaning of applicable securities laws. These statements
reflect what Biophan anticipates, expects, or believes may happen in the future.
Biophan's actual results could differ materially from the outcome or
circumstance expressed or implied by such forward-looking statements as a result
of a variety of factors including, but not limited to: Biophan's ability to
develop its technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development programs; the
ability of Biophan to demonstrate the effectiveness of its technology; the
acceptance by the market of Biophan's technology and products incorporating such
technology, the ability of Biophan to effectively negotiate and enter into
contracts with medical device manufacturers for the licensing of Biophan's
technology; competition; the ability of Biophan to raise capital to fund its
operating and research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in Biophan's
periodic filings with the Securities and Exchange Commission (the "SEC"). As a
result, this press release should be read in conjunction with Biophan's periodic
filings with the SEC which are incorporated herein by reference. The
forward-looking statements contained herein are made only as of the date of this
press release, and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Biophan Technologies, Inc.
CONTACT: Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Jennifer Gould, 212-843-8037
Copyright Business Wire 2005
-0-
KEYWORD: United States
North America
New York
INDUSTRY KEYWORD: Health
Biotechnology
Hospitals
Medical Devices
Oncology
Pharmaceutical
Radiology
Research & Science
Professional Services
Finance
SUBJECT CODE: Product/Service
Trade Show
*** end of story ***
TINY- Stephens initiates coverage with overweight rating..
Jun 22, 2005 (streetinsider.com via COMTEX) -- Stephens initiated coverage on Harris & Harris Group, Inc. (Nasdaq: TINY) with an Overweight rating. Initiating
with a $15 target as a "pure-play" nanotech company on valuation.
StreetInsider.com Premium is also available to Bloomberg Terminal users.
Bloomberg users type STIN <GO> for more information.
CONTACT: StreetInsider.com, Inc.
US Toll Free: 800-323-0153
info@streetinsider.com
http://www.streetinsider.com
august gold settled + .50 to 440.50.
raise stops from 426 to 430.10 spot....
august gold settled unchanged @ 440.00.
invs who missed getting long @ the + 428 spot brk/out lvl & those wishing 2 re enter,
can buy current correction down to 432 spot area & lower,
with a 426 stop...
upside targets r 441 & 470 spot...
Biophan and New Scale Announce SQUIGGLE Motor Named to EE Time' Top Ten ''Most Significant'' Products List
ROCHESTER, N.Y., Jun 20, 2005 (BUSINESS WIRE) -- Biophan Technologies, Inc.
(OTCBB:BIPH), a developer of next-generation biomedical technology, and New
Scale Technologies, Inc., a developer of miniature ceramic motors, have
announced that the SQUIGGLE (R) motor was named an "ULTIMATE PRODUCT" in the
June 6 issue of EE Times. The SQUIGGLE motor is a linear motor with nanometer
precision, made of piezoelectric ceramics and other non-magnetic materials,
making it safe and compatible for use with Magnetic Resonance Imaging (MRI) for
both implantable and robotic applications.
EE Times is a weekly technical journal read by more than 150,000 design and
development engineers and technical managers. It is consistently chosen as the
best-read and most preferred publication in the industry.
To create the ULTIMATE PRODUCTS report, the magazine's technical editors
selected up to 10 of the most significant products introduced during the
quarter, in each of seven categories. They then invited selected readers of EE
Times and eeProductCenter to rate these products on "technical significance" and
"likelihood of use."
The SQUIGGLE motor was voted # 4 for technical significance in the
Interconnects, Packaging and Electromechanical products (IP&E) section of the
ULTIMATE PRODUCTS 2.1 report (http://www.eeproductcenter.com/ultimate/2.1)
One EE Times reader commented; "As an engineer in the MRI field, I could see the
SQUIGGLE motor becoming an integral part of MRI-compatible devices."
SQUIGGLE motors are available for immediate delivery from New Scale Technologies
and from Biophan, New Scale's exclusive distributor of SQUIGGLE motors for
medical applications.
About New Scale Technologies
New Scale Technologies, Inc. (www.newscaletech.com) makes miniature ceramic
motors that enable our customers to create smaller products. New Scale's
patented SQUIGGLE motors are bigger than MEMS devices but smaller than
conventional motors. New Scale generates precise movement using ultrasonic
vibrations, which makes our piezoelectric motors powerful, precise, simple, and
compatible with extreme environments.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make
biomedical devices safe and compatible with the magnetic resonance imaging (MRI)
environment. The Company develops enabling technologies for implanted medical
systems such as pacemakers and interventional surgical devices such as
catheters, guidewires, stents, and other implants to allow them to be safely and
effectively imaged under MRI. The technology is also being used to create MRI
contrast agents, and has expanded to include other applications, such as drug
delivery and power systems derived from body heat. Four Biophan technologies
include advances in nanotechnology and thin film coatings. Committed to growth
through innovation and developmental leadership, Biophan and its licensors now
hold a total of 127 U.S. patents, licenses, or applications. This total includes
37 issued U.S. patents, 8 recently-allowed applications that will issue as
patents in the near future, and 82 pending applications at various stages of
examination at the U.S. Patent and Trademark Office, plus international
applications. The patents cover areas including nanotechnology (nanomagnetic
particle coatings), radio frequency filters, polymer composites, thermoelectric
materials for batteries generating power from body heat, and photonics. Biophan
has joint development arrangements with Boston Scientific (NYSE:BSX - News) and
NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical
devices capable of safely and successfully working with MRI, and delivering
other technologies which will improve quality of life. For more information,
please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking
statements within the meaning of applicable securities laws. These statements
reflect what Biophan anticipates, expects, or believes may happen in the future.
Biophan's actual results could differ materially from the outcome or
circumstance expressed or implied by such forward-looking statements as a result
of a variety of factors including, but not limited to: Biophan's ability to
develop its technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development programs; the
ability of Biophan to demonstrate the effectiveness of its technology; the
acceptance by the market of Biophan's technology and products incorporating such
technology, the ability of Biophan to effectively negotiate and enter into
contracts with medical device manufacturers for the licensing of Biophan's
technology; competition; the ability of Biophan to raise capital to fund its
operating and research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in Biophan's
periodic filings with the Securities and Exchange Commission (the "SEC"). As a
result, this press release should be read in conjunction with Biophan's periodic
filings with the SEC which are incorporated herein by reference. The
forward-looking statements contained herein are made only as of the date of this
press release, and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Biophan Technologies, Inc.
CONTACT: New Scale Technologies, Inc.
Fred Haas, 585-924-4450
Fax 585-924-4468
fhaas@newscaletech.com
or
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2441
chotchkiss@biophan.com
Copyright Business Wire 2005
-0-
KEYWORD: United States
Germany
Europe
North America
New York
INDUSTRY KEYWORD: Technology
Other Technology
Health
Biotechnology
Hospitals
Radiology
Research & Science
Other Health
Professional Services
Finance
SUBJECT CODE: Product/Service
*** end of story ***
Biophan Sets Exclusive License For MRI Visualization Of Implant
ed Stents ( financialwire.net )
Jun 17, 2005 (financialwire.net via COMTEX) -- June 17, 2005 (FinancialWire)
Biophan Technologies, Inc. (OTCBB: BIPH) said it has finalized an exclusive
license with leading German biomedical researchers, Dr. Arno Bucker and Dr.
Alexander Ruebben, for their breakthrough stent technology enabling accurate
Magnetic Resonance Imaging (MRI) in or around metallic stents.
MRI has not been able to visualize the interior of metallic stents, because
current generations of stents create image artifacts and do not allow
visualization of the stent lumen. Procedures such as MR vessel wall imaging and
plaque imaging are not possible in the stented vessel segments.
The new technology developed at the Radiology Department of Professor Gunther at
the University Hospital in Aachen uses a special design and material. The
imaging of stent interiors by traditional X-ray angiography requires an invasive
procedure and only allows visualization of the vessel lumen. Biophan's newly
licensed solution is designed to enable non-invasive, safer, less costly and
more useful MRI-based imaging of stent interiors and the adjacent vessel walls.
One possible additional advantage is that molecular research on the effects and
physiology of drug eluting stents could be carried out non-invasively by MRI.
Together with the existing technologies already held by Biophan, including those
obtained through the Company's recent acquisition of aMRIs GmbH, the exclusive
license with Dr Bucker and Dr. Ruebben will give Biophan licensing ownership to
two of the most promising methods to create artifact-free images of stents and
implants with MRI systems. "The technologies are very synergistic and the
combination could prove to be very beneficial," commented Michael Friebe, PhD,
CEO of Biophan Europe. "We now have the only proven methods for non-invasive
imaging of stent performance."
Dr. Bucker, a clinical professor of radiology at the University of Aachen, is
one of the leading experts in interventional MR. The University of Aachen is a
renowned clinical research institution and one of the leading radiology research
centers in the world and is led by Prof. Rolf W. Gunther. Dr. Bucker will
continue to work on further improvements to the licensed technology together
with Biophan Europe. Dr. Ruebben, a former radiologist from Aachen University
Hospital and now CEO of Aachen Resonance, will also assist in further advancing
the research on MRI compatible stents together with Biophan Europe.
Due to its excellent image quality, diagnostic accuracy, and overall safety,
MRI-based angiography is increasingly replacing diagnostic X-ray angiography for
vascular imaging throughout the body.
Biophan is enrolled in Beacon Equity Research's professional analyst program,
which facilitates independent analysts to provide financial coverage for
shareholders and investors in companies that otherwise would have little or no
analyst following. Enrollment in standards-based research is an important
measure of a company's commitment to transparency and Good Governance.
On March 14, 2005, Beacon analyst Shailesh Dhuri, CFA, issued a preliminary
Research Note, and is preparing a comprehensive report.
Beacon Equity Research, LLC is a fee-based, comprehensive investment research
firm, focusing primarily on the underserved small-cap sector. All Beacon
analysts are seasoned industry professionals and adhere to the CFA Institute's
(CFAI) stringent ethics and standards of practice guidelines. Beacon Research
does not have any investment banking relationships with any of the companies
covered. All analysts are compensated prior to performing their investment
research and are not compensated in any way based on the future performance of
the equities they follow.
Both Beacon Equity Research and Investrend Research subscribe to the "Standards
for Independent Research Providers" at http://www.firstresearchconsortium.com,
and adhere to the Guidelines for independent providers jointly endorsed by the
National Investor Relations Institute (http://www.niri.org) and the CFA
Institute (http://www.cfainstitute.org)
Beacon is being compensated $18,000 for a year's coverage.
The Dow Jones Newswires has stated that independent research has been growing in
credibility over the past 18 months, specifically citing Investrend Research,
and the New York Times has reported a survey by Charles Schwab & Co. reveals an
astonishing 78 percent of active stockholders now "value research from
independent firms over analysis by Wall Street firms with financial ties to the
companies they are rating." A survey at Investopedia reveals that 74.7% of
investors say that "legitimate fee-based research is objective and useful," and
70.9% say that a company that enrolls for "legitimate fee-based research is
making a positive statement about its investment potential."
There are never any fees associated with FinancialWire, which independently
covers a wide range of corporate news, including but not limited to those that
are or have been enrolled in Investrend's platforms.
Complete information about any company enrolled in an Investrend shareholder
empowerment platform, including those of its affiliates and independent analysts
and webcasters, including disclosures and disclaimers, is available at the
company's InvestorPower page at
http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report
and press release, and investors are advised to read those disclosures carefully
before trading in the equities of any enrolled company.
For up-to-the-minute news, features and links click on
http://www.financialwire.net
FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
http://www.investrend.com/contact.asp
The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268
URL: http://www.financialwire.net
(C) 2005 financialwire.net, Inc. All rights reserved.
-0-
*** end of story ***
on Tuesday, spot gold failed @ the 424-426 level..
another test of 418 is possible: below 418,
the last leg down to 400 is likely..
a cycle turn for the usd is due on 6/17,
& cud b a high..
wud only buy +428 with stops.....
Biophan CEO Michael Weiner to Present Advanced Biomedical Solutions and Business Plan at NanoEquity Europe Conference 2005, June 13-14; CEO to Discuss Strategy to Commercialize Company's Proprietary Nanotechnologies
ROCHESTER, N.Y., Jun 09, 2005 (BUSINESS WIRE) -- Biophan Technologies, Inc.
(OTCBB: BIPH), a developer of next-generation medical technology, will present
an overview of its innovative nanotechnologies for the biomedical sector, and
key aspects of its business strategy to ensure growth through protection and
enforcement of patents, as a featured company at the NanoEquity Europe
Conference 2005, June 13-14, at the Hilton Hotel in Frankfurt, Germany.
Biophan CEO Michael Weiner will make the presentation, entitled, "Converting
Nanotechnologies into Shareholder Value." His presentation is designed to
highlight the Company's range of innovative nanotechnology solutions, patent
portfolio, and proprietary technologies. "Many of Biophan's institutional and
individual shareholders are based in Germany," Mr. Weiner said. "I am looking
forward to updating them on our progress at this important international
nanotechnology conference. The Frankfurt Stock Exchange has been an important
contributor to our overall trading volume and growing shareholder base. We are
very pleased to be invited back again this year." Mr. Weiner's presentation is
scheduled for 11:10 am, Tuesday, June 14, in the Liberty II room.
Biophan's intellectual property portfolio contains 127 U.S. issued, pending, and
exclusively licensed patents, in addition to 46 international issued and pending
patents. Biophan is developing a range of next-generation nanotechnology-based
solutions, including technologies to make implanted biomedical devices and
surgical instruments safe and image compatible for use in Magnetic Resonance
Imaging (MRI) environments. Biophan will present its nanotechnology applications
for controlling drug release from coated surfaces, and for limiting the toxic
effects of powerful drugs. An update on the progress of its biothermal battery,
powered by body heat, will also be included in the presentation, as will images
of its MRI imageable stents and vena cava filters.
For more information about the First NanoEquity Europe Conference 2005, please
visit http://www.deutsche-boerse.com.
About NanoEquity Europe Conference 2005
The NanoEquity Europe Conference is sponsored by Deutsche Borse Group, owner of
Frankfurt Stock Exchange, Europe's largest stock exchange. Its goal is to create
a greater long-term awareness on the domestic and international capital markets
for companies from the sectors high-tech engineering - with this particular
event focusing on nano- and micro technologies. The conference aims to present
issues related to the capital market and the acquisition of equity for companies
from all areas of nano- and micro technology. It will bring together academic
experts and decision makers from companies and the capital markets. The
conference will be held in German and English.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make
biomedical devices safe and compatible with the magnetic resonance imaging (MRI)
environment. The Company develops enabling technologies for implanted medical
systems such as pacemakers and interventional surgical devices such as
catheters, guidewires, stents, and other implants to allow them to be safely and
effectively imaged under MRI. The technology is also being used to create MRI
contrast agents, and has expanded to include other applications, such as drug
delivery and power systems derived from body heat. Four Biophan technologies
include advances in nanotechnology and thin film coatings. Committed to growth
through innovation and developmental leadership, Biophan and its licensors now
hold a total of 127 U.S. patents, licenses, or applications. This total includes
37 issued U.S. patents, 8 recently-allowed applications that will issue as
patents in the near future, and 82 pending applications at various stages of
examination at the U.S. Patent and Trademark Office, plus international
applications. The patents cover areas including nanotechnology (nanomagnetic
particle coatings), radio frequency filters, polymer composites, thermoelectric
materials for batteries generating power from body heat, and photonics. Biophan
has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's
Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices
capable of safely and successfully working with MRI, and delivering other
technologies which will improve quality of life. For more information, please
visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking
statements within the meaning of applicable securities laws. These statements
reflect what Biophan anticipates, expects, or believes may happen in the future.
Biophan's actual results could differ materially from the outcome or
circumstance expressed or implied by such forward-looking statements as a result
of a variety of factors including, but not limited to: Biophan's ability to
develop its technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development programs; the
ability of Biophan to demonstrate the effectiveness of its technology; the
acceptance by the market of Biophan's technology and products incorporating such
technology, the ability of Biophan to effectively negotiate and enter into
contracts with medical device manufacturers for the licensing of Biophan's
technology; competition; the ability of Biophan to raise capital to fund its
operating and research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in Biophan's
periodic filings with the Securities and Exchange Commission (the "SEC"). As a
result, this press release should be read in conjunction with Biophan's periodic
filings with the SEC which are incorporated herein by reference. The
forward-looking statements contained herein are made only as of the date of this
press release, and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Biophan Technologies, Inc.
CONTACT: Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Jennifer Gould, 212-843-8037
Copyright Business Wire 2005
-0-
KEYWORD: United States
Germany
Europe
North America
New York
INDUSTRY KEYWORD: Technology
Other Technology
Health
Biotechnology
Hospitals
Medical Devices
Oncology
Radiology
Research & Science
Professional Services
Finance
SUBJECT CODE: Trade Show
*** end of story ***
August Gold has been creeping up, settling + 1.00 to close @ 425.80 on Friday. 424 spot is key & the metal needs 2 hold above 424 after Tuesday. There remains a 1 month window where a test of 400 spot is still possible. It shud b noted that on 6/02, gold stks failed 2 respond to the +$7.10 spike in August Gold.
A cycle turn for gold is due Monday/Tuesday.If it turns out 2 b a low with a higher bottom, long positions shud b initiated....
same o, same o:
selling doesn't cause declining prices,
declining prices cause selling....
Biophan CEO Michael Weiner Speaks about Company's Intellectual Property Expansion in Interview with BiomedDiscoveries.com
Biophan Continues to Strengthen Patent Portfolio with a Variety of Groundbreaking Solutions for Biomedical Devices
LOS ANGELES, Jun 2, 2005 (PRIMEZONE via COMTEX) -- BiomedDiscoveries.com,
http://www.BiomedDiscoveries.com, the online source for exclusive investor
information in the biotechnology sector, has announced the availability of an
online interview with Michael Weiner, CEO of Biophan Technologies (OTCBB:BIPH),
a developer of next-generation medical technology.
Biophan has recently announced the filing of 13 new patent applications,
expanding its intellectual property portfolio to 127 U.S. issued, pending, and
exclusively licensed patents, in addition to 46 international issued and pending
patents.
In the interview, Mr. Weiner focuses on the Company's new patent applications,
which he describes as varying in scope and detail, but all integral to the
Company's "patent thicket" business strategy to ensure market leadership. That
strategy seeks to safeguard Biophan's intellectual property and minimize any
chances of copycat competition by casting a wide patent net around its
technological innovations.
The technologies described in its new patent applications expand Biophan's
coverage of nanomagnetic and other device coatings, specialized dielectric
materials, biothermal power sources, certain photonic diagnostics and therapies,
and other innovations. Many of the Company's technologies provide solutions to
ensure safety and image compatibility of implanted and interventional medical
devices with Magnetic Resonance Imaging (MRI) diagnostic equipment.
A growing body of published medical research is drawing attention to the need
for improved safety and visualization of MRI imaging with pacemakers and other
implanted devices, many of which are currently contraindicated for use in MRI
systems. The electromagnetic environments of MRI can cause many of these devices
to heat up dangerously, to create induced voltages, or to malfunction,
potentially causing serious harm or death to patients. Other devices such as
stents are safe for use with MRI, but interfere with imaging by MRI, which
limits their functionality. Biophan has technologies to address both of these
limitations.
In the interview, Mr. Weiner also discusses the relative economic efficiency of
the Company's research and development initiatives, noting that most technology
companies typically spend far more to develop their intellectual property on a
per-patent basis. The interview is available online at
http://www.BiomedDiscoveries.com.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make
biomedical devices safe and compatible with the magnetic resonance imaging (MRI)
environment. The Company develops enabling technologies for implanted medical
systems such as pacemakers and interventional surgical devices such as
catheters, guidewires, stents, and other implants to allow them to be safely and
effectively imaged under MRI. The technology is also being used to create MRI
contrast agents, and has expanded to include other applications, such as drug
delivery and power systems derived from body heat. Four Biophan technologies
include advances in nanotechnology and thin film coatings. Committed to growth
through innovation and developmental leadership, Biophan and its licensors now
hold a total of 127 U.S. patents, licenses, or applications. This total includes
36 issued U.S. patents, 9 recently-allowed applications that will issue as
patents in the near future, and 82 pending applications at various stages of
examination at the U.S. Patent and Trademark Office, plus international
applications. The patents cover areas including nanotechnology (nanomagnetic
particle coatings), radio frequency filters, polymer composites, thermoelectric
materials for batteries generating power from body heat, and photonics. Biophan
has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's
Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices
capable of safely and successfully working with MRI, and delivering other
technologies which will improve quality of life. For more information, please
visit www.biophan.com.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research, interviews and
other information about the smallcap investment marketplace.
BiomedDiscoveries.com strives to provide investors with information and
research-based data regarding important individual companies and overall
marketplace trends. Resources available on BiomedDiscoveries.com include audio
interviews with corporate leaders and respected commentators, as well as
technical white papers and other forms of market and investment analysis. It is
located at http://www.BiomedDiscoveries.com.
Forward-Looking Statements
Statements made on BiomedDiscoveries.com may contain forward-looking statements
made by senior management of the companies presented here that involve risks and
uncertainties, such as statements about plans, objectives, expectations,
assumptions or future events. These statements involve estimates, assumptions,
known and unknown risks, uncertainties and performances, or achievements
expressed or implied by the forward-looking statements. Actual future results
and trends may differ materially from those made in -- or suggested by --
statements presented here due to a variety of factors. Consequently, you should
not place undue reliance on any forward-looking statements made here. Many of
these and other risks and uncertainties are discussed in greater detail in
recent filings with the Securities Exchange Commission for the companies that
are present by BiomedDiscoveries.com. Compensation and Other Disclosures
BiomedDiscoveries.com is a wholly-owned subsidiary of Trilogy Capital Partners,
Inc. Trilogy Capital Partners provides investor relations services to public
companies. The companies presented by BiomedDiscoveries.com are usually clients
of Trilogy Capital Partners and compensate Trilogy Capital Partners for these
services, including cash compensation and equity securities. In addition,
Trilogy Capital Partners and its affiliates may own securities of the presenting
companies, and may from time to time purchase and sell securities of these
companies in the open market or in private transactions. Biophan Technologies
pays Trilogy $12,500 per month for so long as Trilogy is retained to provide
investor relations services. A subsidiary of Trilogy has entered into an
agreement with a non-affiliate shareholder of this company to purchase from the
shareholder 880,000 shares at $.80 per share and 4,180,000 shares at $2.00 per
share at such time as the shareholder has purchased the shares from by this
company at the same prices. The shareholder is obligated to purchase these
shares only if this company has registered the shareholder's resale of the
shares under the Securities Act of 1933 and certain other conditions are
satisfied.
SOURCE: BioMedDiscoveries.com
By Staff
CONTACT: BiomedDiscoveries.com
Astra Gomez
(800) 592-6061
euro: they finally got down to 1.2490 to run the stops...
Biophan Further Expands Intellectual Property Portfolio to 127 U.S. Issued and Pending Patents and 46 International Patents
Friday May 27, 3:30 am ET
Company Executes Strategy to Maintain Commanding Lead in MRI Safety and Visualization for Medical Devices and Innovations in Extended Battery Life
ROCHESTER, N.Y.--(BUSINESS WIRE)--May 27, 2005-- Biophan Technologies, Inc. (OTCBB: BIPH - News), a developer of next-generation medical technology, today announced that its intellectual property portfolio has grown by an additional 13 patent applications, to reach 127 U.S. issued or pending patents. The new patents cover Biophan technologies that provide improvements in Magnetic Resonance Imaging (MRI) safety and imaging of implanted devices and surgical tools, as well as technologies for implantable power sources using body heat. Additionally, the Company has 46 issued or pending international patents.
ADVERTISEMENT
These new applications expand Biophan's coverage of nanomagnetic and other device coatings, specialized dielectric materials, biothermal power sources, certain photonic diagnostics and therapies, and other innovations. A patent application focusing on the use of photonic technology for MRI sensing coils that operate inside body cavities has recently been allowed by the U.S. Patent and Trademark Office (USPTO) for issuance in the near future.
A second application allowed by the USPTO covers an active compensation component designed for use with pacemakers and similar devices to eliminate the potentially lethal risk from pulsed magnetic fields in MRI by eliminating the ability of these fields to cause ventricular fibrillation during an MRI procedure. This additional capability to eliminate the danger of induced voltages can allow pacemaker manufacturers to develop devices that are truly safe with MRI. Currently, all pacemakers are still contraindicated for use with MRI. Building Biophan's solutions into future devices may allow patients to safely undergo MRI scans in the future.
The new patent applications extend Biophan's nanotechnology patents, as well as patents related to other technologies that solve critical MRI safety and imaging problems related to the use of MRI with medical devices such as pacemakers, defibrillators, neurostimulators, stents, catheters, and guidewires.
A growing body of published medical research has drawn attention to the need for improved safety and visualization of MRI imaging with these devices. Leading medical device makers, such as Medtronic Inc. and Guidant Corp., as well as the FDA, have publicly expressed the need for technology solutions that will make the use of MRI both safe and effective for the increasing number of patients receiving these devices.
A recent issue of the medical journal, Pacing and Clinical Electrophysiology (PACE), reported on the increasing recognition throughout the medical community of the need to develop pacemakers and other devices that can be safely used within the powerful electromagnetic environments of MRI systems.
"Biophan appears to dominate the patent coverage of solutions for these MRI safety and visualization problems, at a time when industry interest in finding solutions is increasing," said Michael Weiner, CEO of Biophan. "We are seeing confirmation of this by the number of companies we are in discussions with who have expressed interest in our technology, in addition to the deals on specific devices that we are close to closure on and have previously disclosed."
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 127 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 82 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws
on thursday, June Gold settled - 1.10 to 420.80...friday is a cycle turn day for gold:
buy regaining 424(spot) or below 418, luk
4 a test of 411 to initiate longs...
tgal: either that, or sum of the nano
money is flowing back in....
on Friday, June Gold continued down on usd strength,
hitting a low of 424.50, before settling dwn 3.80
to close @ 426.90...
remain a buyer -410 or + 434 basis spot:
in between, just a lot of chop...
June Gold continued its brkdwn & settled
-5.60 to 430.50, holding 430 sppt..
..most of selling appeared 2 be by funds
& bullion banks in reaction 2 the weak usd...
luk 2 reenter long on a spike dwn -412 basis spot or
on regaining 436...wud continue to avoid gold stks in
the interim...